Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: Multicenter phase II So.LAR. study

Cancer Chemotherapy and Pharmacology

Volumn 66, Issue 5, 2010, Pages 837-844

  Prete, Salvatore Del ^a   Montella, Liliana ^a   Caraglia, Michele ^c   Maiorino, Luigi ^b   Cennamo, Gregorio ^a   Montesarchio, Vincenzo ^d   Piai, Guido ^e   Febbraro, Antonio ^f   Tarantino, Luciano ^a   Capasso, Elena ^g   Palmieri, Giovannella ^h   Guarrasi, Rosario ^a   Bianco, Maddalena ⁱ   Mamone, Rosanna ^a   Savastano, Clementina ^j   Pisano, Agata ^k   Vincenzi, Bruno ^l   Sabia, Antonietta ^m   D'Agostino, Alberto ⁿ   Faiola, Vincenzo ^a   Addeo, Raffaele ^a   more..

^a SAN GIOVANNI DI DIO HOSPITAL   (Italy)

^b San Gennaro Hospital   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d AO Dei Colli Hospital for Infectious Diseases D Cotugno   (Italy)

^e AOS Sebastiano   (Italy)

^f Medical Oncology   (Italy)

^g Senology Unit   (Italy)

^h UNIVERSITY OF NAPLES FEDERICO II   (Italy)

ⁱ Ospedale S Leonardo   (Italy)

^j S Giovanni di Dio   (Italy)

^k S Maria delle Grazie Hospital   (Italy)

^l UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^m Medical Oncology Unit   (Italy)

ⁿ Surgery Division Unit   (Italy)

more..

Author keywords

Hepatocellular carcinoma; Long acting octreotide; Sorafenib

Indexed keywords

OCTREOTIDE; SORAFENIB;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTHRALGIA; ARTICLE; BLEEDING; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HOARSENESS; HUMAN; HYPERTENSION; HYPOTHYROIDISM; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TRANSPLANTATION; MALE; MULTICENTER STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROCTALGIA; RADIOFREQUENCY ABLATION; SIDE EFFECT; TREATMENT RESPONSE; VOICE CHANGE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; DIARRHEA; DISEASE PROGRESSION; FEMALE; HUMANS; HYPERTENSION; LIVER NEOPLASMS; MALE; MIDDLE AGED; OCTREOTIDE; PYRIDINES; SURVIVAL; TREATMENT OUTCOME;

EID: 77956228586     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1226-z     Document Type: Article

References (34)

1. R Addeo M Caraglia S Del Prete 2009 Highlights of regional meeting of Italian Southern Oncological Group (GOIM): focus on hepatocellular carcinoma: biological and clinical background, therapeutic guide-lines and perspectives Expert Opin Investig Drugs 18 3 373 378 10.1517/14712590802680158 1:CAS:528:DC%2BD1MXitlWrtL8%3D 19243288 (7 Nov 2008, Naples, Italy)
2. M Caraglia P Tassone M Marra, et al. 2006 Targeting Raf-kinase: molecular rationales and translational issues Ann Oncol 17 Suppl 7 vii124 vii127 10.1093/annonc/mdl964 16760274
3. CH Takimoto A Awada 2008 Safety and anti-tumor activity of sorafenib (Nexavar®) in combination with other anti-cancer agents: a review of clinical trials Cancer Chemother Pharmacol 61 535 548 10.1007/s00280-007-0639-9 1:CAS:528:DC%2BD1cXjsFWltw%3D%3D 18026728
4. JM Llovet S Ricci V Mazzaferro, et al. 2008 SHARP Investigators Study Group Sorafenib in advanced hepatocellular carcinoma N Engl J Med 24 359 378 390 10.1056/NEJMoa0708857
5. AL Cheng YK Kang Z Chen, et al. 2009 Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Lancet Oncol 10 25 34 10.1016/S1470-2045(08)70285-7 1:CAS:528:DC%2BD1cXhsFChtbnM 19095497
6. MB Thomas JL Abbruzzese 2008 Opportunities for targeted therapies in hepatocellular carcinoma J Clin Oncol 23 8093 8108 10.1200/JCO.2004.00.1537
7. JM Llovet J Bruix 2008 Molecular targeted therapies in hepatocellular carcinoma Hepatology 48 1312 1327 10.1002/hep.22506 1:CAS:528:DC%2BD1cXht1Khu7zP 18821591
8. JM Llovet A Di Bisceglie J Bruix, et al. 2008 Design and end-points of clinical trials in HCC J Natl Cancer Inst 100 698 711 10.1093/jnci/djn134 18477802
9. L Buscail F Vernejoul P Faure J Torrisani C Susini 2002 Regulation of cell proliferation by somatostatin Ann Endocrinol (Paris) 63 2S13 2S18 1:CAS:528:DC%2BD38XlsV2qsrw%3D
10. AL Hagemeister MA Sheridan 2008 Somatostatin inhibits hepatic growth hormone receptor and insulin-like growth factor I mRNA expression by activating the ERK and PI3K signaling pathways Am J Physiol Regul Integr Comp Physiol 295 R490 R497 1:CAS:528:DC%2BD1cXhtVakt7nO 18495839
11. M Zhao JA Laissue A Zimmermann 1993 "Neuroendocrine" differentiation in hepatocellular carcinomas (HCCs): immunohistochemical reactivity is related to distinct tumor cell types, but not to tumor grade Histol Histopathol 8 617 626 1:STN:280:DyaK2c7jvVWktw%3D%3D 8305816
12. E Kouroumalis P Skordilis K Thermos, et al. 1998 Treatment of hepatocellular carcinoma with octreotide: a randomized controlled study Gut 42 442 447 10.1136/gut.42.3.442 1:CAS:528:DyaK1cXitlyrtL4%3D 9577356
13. JC Reubi A Zimmermann S Jonas, et al. 1999 Regulatory peptide receptors in human hepatocellular carcinomas Gut 45 766 774 10.1136/gut.45.5.766 1:CAS:528:DyaK1MXnt1Clurs%3D 10517918
14. JT Siveke C Herberhold C Folwaczny 2003 Complete regression of advanced HCC with long acting octreotide Gut 52 1531 10.1136/gut.52.10.1531-a 1:STN:280:DC%2BD3svivFWmtQ%3D%3D 12970151
15. DN Samonakis J Moschandreas T Arnaoutis, et al. 2002 Treatment of hepatocellular carcinoma with long acting somatostatin analogues Oncol Rep 9 903 907 1:CAS:528:DC%2BD38XltlGrs7c%3D 12066229
16. D Dimitroulopoulos D Xinopoulos K Tsamakidis, et al. 2002 The role of Sandostatin LAR in treating patients with advanced hepatocellular cancer Hepatogastroenterology 49 1245 1250 1:CAS:528:DC%2BD38Xnslegsr4%3D 12239914
17. M Raderer MH Hejna C Muller, et al. 2000 Treatment of hepatocellular cancer with the long acting somatostatin analog lanreotide in vitro and in vivo Int J Oncol 16 1197 1201 1:CAS:528:DC%2BD3cXjvVWhs7s%3D 10811995
18. J Cebon Australasian Gastro-Intestinal Trials Group (AGITG) AG000IH Investigators 2006 Somatostatin receptor expression, tumor response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide Br J Cancer 95 853 861 10.1038/sj.bjc.6603325 1:CAS:528:DC%2BD28XhtVans7jO 16953241
19. G Becker HP Allgaier M Olschewski, et al. 2007 HECTOR Study Group. Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study Hepatology 45 9 15 10.1002/hep.21468 1:CAS:528:DC%2BD2sXht1arsLg%3D 17187405
20. DN Samonakis G Notas N Christodoulakis EA Kouroumalis 2008 Mechanisms of action and resistance of somatostatin analogues for the treatment of hepatocellular carcinoma: a message not well taken Dig Dis Sci 53 2359 2365 10.1007/s10620-007-0175-9 18273705
21. L Montella R Addeo M Caraglia, et al. 2008 Vascular endothelial growth factor monitoring in advanced hepatocellular carcinoma patients treated with radiofrequency ablation plus octreotide: a single center experience Oncol Rep 20 385 390 1:CAS:528:DC%2BD1cXhtVOrtrnL 18636202
22. P Therasse G Susan SG Arbuck, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 205 216 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D 10655437
23. R Simon 1989 Optimal two-stage designs for phase II clinical trials Control Clin Trials 10 1 10 10.1016/0197-2456(89)90015-9 1:STN:280: DyaL1M7ps1SjsQ%3D%3D 2702835
24. E Kaplan P Meier 1958 Nonparametric estimation from incomplete observations J Am Stat Assoc 53 457 481 10.2307/2281868
25. TWT Leung YZ Patt W Lau, et al. 1999 Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma Clin Cancer Res 5 1676 1681 1:CAS:528:DyaK1MXltVCqsbc%3D 10430068
26. GK Abou-Alfa L Schwartz S Ricci D Amadori A Santoro A Figer J De Greve J-Y Douillard C Lathia B Schwartz I Taylor M Moscovici LB Saltz 2006 Phase II study of sorafenib in patients with advanced hepatocellular carcinoma J Clin Oncol 24 4293 4300 10.1200/JCO.2005.01.3441 1:CAS:528:DC%2BD28XhtVGju7jE 16908937
27. H Minami K Kawada H Ebi K Kitagawa YI Kim K Araki H Mukai M Tahara H Nakajima K Nakajima 2008 Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors Cancer Sci 99 1492 1498 10.1111/j.1349-7006.2008.00837.x 1:CAS:528:DC%2BD1cXot1eitb4%3D 18477034
28. J Furuse H Ishii K Nakachi E Suzuki S Shimizu K Nakajima 2008 Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma Cancer Sci 99 159 165 1:CAS:528:DC%2BD1cXnsFWltQ%3D%3D 17953709
29. D Strumberg JW Clark A Awada MJ Moore H Richly A Hendlisz HW Hirte JP Eder HJ Lenz B Schwartz 2007 Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors Oncologist 12 426 437 10.1634/theoncologist.12- 4-426 1:CAS:528:DC%2BD2sXmtlSitrs%3D 17470685
30. SJ Faivre E Raymond J Douillard, et al. 2007 Assessment of safety and drug-induced tumor necrosis with sunitinib in patients (pts) with unresectable hepatocellular carcinoma (HCC) J Clin Oncol 25 149s (Suppl; abstr 3546)
31. AX Zhu 2008 Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma Cancer 112 250 259 10.1002/cncr.23175 1:CAS:528:DC%2BD1cXhs12gsbs%3D 18041064
32. PA Philip MR Mahoney C Allmer, et al. 2005 Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer J Clin Oncol 23 6657 6663 10.1200/JCO.2005.14.696 1:CAS:528:DC%2BD2MXhtFWqsLbJ 16170173
33. MB Thomas R Chadha K Glover, et al. 2007 Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma Cancer 110 1059 1066 10.1002/cncr.22886 1:CAS:528:DC%2BD2sXhtVChs7fJ 17623837
34. T Yau P Chan KK Ng, et al. 2009 Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response Cancer 115 428 436 10.1002/cncr.24029 1:CAS:528:DC%2BD1MXhvFCiurk%3D 19107763